Related Experiment Video

Updated: Aug 9, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Preliminary experience with bosentan as initial therapy in childhood idiopathic pulmonary arterial hypertension

Catherine M Simpson1, Daniel J Penny, Andrew D Cochrane

  • 1Department of Cardiology, The Royal Children's Hospital, Melbourne, Victoria, Australia.

The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|March 28, 2006
PubMed

Insights

Treatment with bosentan improved survival in children with idiopathic pulmonary arterial hypertension (IPAH). This therapy may delay disease progression in pediatric patients diagnosed with IPAH.

Area of Science:

  • Pediatric pulmonology
  • Cardiovascular research
  • Rare disease treatment

Background:

  • Childhood idiopathic pulmonary arterial hypertension (IPAH) is a severe and fatal condition.
  • Conventional therapies have limited efficacy in managing IPAH progression.
  • Newer treatment strategies are needed to improve outcomes for affected children.

Purpose of the Study:

  • To evaluate the efficacy of bosentan in combination with other therapies for childhood IPAH.
  • To compare survival rates and clinical status of bosentan-treated patients with historic controls.
  • To assess the impact of bosentan on IPAH disease progression.

Main Methods:

  • Retrospective analysis of 7 consecutive pediatric IPAH patients treated with bosentan and other therapies (sildenafil/warfarin/epoprostenol) since 2001.
  • Comparison with a cohort of 12 historic control patients diagnosed before 1997 receiving conventional therapy.
  • Survival analysis using log-rank test to compare treatment groups based on disease severity.

Main Results:

  • Bosentan-treated patients demonstrated improved survival compared to historic controls with similar disease severity (log rank, p = 0.04).
  • Combination therapy including bosentan showed a trend towards delaying IPAH disease progression.
  • Clinical status and survival benefits were observed in the bosentan treatment group.

Conclusions:

  • Bosentan, in combination with other therapies, offers a survival benefit for children with IPAH.
  • This treatment approach may delay the progression of childhood idiopathic pulmonary arterial hypertension.
  • Findings support bosentan as a valuable therapeutic option for pediatric IPAH management.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...